Advancements in Cancer Therapy: OncoNano's Breakthrough with muONM-412 Nanoparticles

At the AACR Annual Meeting 2024, OncoNano Medicine's presentation elucidates the preclinical efficacy and safety profile of muONM-412, an encapsulated murine interleukin-12 fusion protein (IL-12Fc) within ON-BOARD™ nanoparticles. This innovative approach addresses the longstanding challenges associated with IL-12 therapy, offering improved tolerability over unencapsulated IL-12Fc while retaining potent antitumor efficacy. Furthermore, the study underscores the favorable stability and pH-responsive bioactivity of ONM-412 in vitro, showcasing the potential of ON-BOARD™ nanoparticle technology to revolutionize targeted oncology treatments and enhance patient outcomes.